RxDoctor Payments Data

Lauren Deichmann

Family · Bridgeton, MONPI 1629366695

Payments from drug & device makers

$748in general payments, 2019–2025

Across 18 payments — averaging $41.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$202
  • Amgen$132
  • Tris Pharma Inc$110
  • Novo Nordisk$108
  • AbbVie$98
  • Neurelis, Inc.$33
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 60th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$43,765
Medicare patients
147
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$44,881
EliquisApixaban19$22,461
MounjaroTirzepatide20$21,099
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,460
FarxigaDapagliflozin Propanediol29$18,541
Semglee (Yfgn) PenInsulin Glargine-Yfgn12$5,325
Duloxetine Hcl53$2,488
Galantamine Hbr21$2,305
Wixela InhubFluticasone Propion/Salmeterol13$2,097
Donepezil Hcl24$1,605
Levothyroxine Sodium68$1,172
Gabapentin78$1,163
Atorvastatin Calcium55$1,117
Pantoprazole Sodium82$1,068
Omeprazole72$1,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$108$44,88142 claims
Lilly USA, LLCMounjaro$202$21,09920 claims
GSKTrelegy Ellipta$16$19,46023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,812 family providers in Missouri.

Other family in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →